EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571)



c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571)



Cancer ChemoTherapy and Pharmacology 50(2): 167-169



Purpose: In order to determine whether Ewing tumour patients may be potential candidates for imatinib mesylate therapy, we analysed the expression of the currently known imatinib mesylate-sensitive tyrosine kinases and tested sensitivity to imatinib mesylate in a panel of eight Ewing tumour cell lines in vitro. Methods: Expression of the different tyrosine kinases was assessed by flow cytometry and RT-PCR. Sensitivity to imatinib mesylate was analysed using a standard MTT proliferation assay. Results: Flow cytometric and RT-PCR analyses in a panel of eight Ewing tumour cell lines demonstrated expression of several imatinib mesylate-sensitive tyrosine kinases, including c-KIT, platelet-derived growth factor receptor, c-ABL and c-ARG. However, in the MTT proliferation assay, all eight Ewing tumour cell lines were found to be resistant to imatinib mesylate at concentrations ranging from 0.1 to 10 muM. Conclusions: Despite the expression of imatinib mesylate-sensitive tyrosine kinases, Ewing tumour cells proved resistant to imatinib mesylate in vitro. This observation has implications for the selection of patients for experimental therapy with imatinib mesylate.

(PDF emailed within 0-6 h: $19.90)

Accession: 011664040

Download citation: RISBibTeXText

PMID: 12172985

DOI: 10.1007/s00280-002-0477-8



Related references

Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. Journal of Biological Chemistry 279(24): 25345-25352, 2004

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571). Sarcoma 2007: 82012-82012, 2008

Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition. International Journal of Molecular Medicine 14(3): 373-382, 2004

Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. Cancer Letters 265(2): 289-297, 2008

An in vitro study of the cytogenetic and cytotoxic effects of imatinib mesylate, STI571 on murine erythroleukemia GM-86 cells. Journal of ChemoTherapy 18(1): 49-55, 2006

The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. Biochemical Pharmacology 77(3): 310-321, 2008

Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 106(7): 2436-2443, 2005

The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro. Leukemia & Lymphoma 44(9): 1549-1555, 2003

Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Research 30(2): 547-552, 2010

Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes. Chemico-Biological Interactions 152(2-3): 139-150, 2005

Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutation Research 603(1): 74-82, 2006

Imatinib mesylate (STI571) for myeloid malignancies other than CML. Leukemia Research 28 Suppl 1: S53-S59, 2004

Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGF-Rα-expressing Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumors (DSRCT). Journal of Clinical Oncology 26(15_suppl): 10547-10547, 2016

Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells. Oncology Reports 23(1): 217-222, 2010

STI571 (imatinib mesylate): the tale of a targeted therapy. Anti-Cancer Drugs 13(2): 111-114, 2002